阿帕替尼用于广泛期小细胞肺癌的疗效和生存分析.

Objective To analyze the efficacy and safety of apatinib in extensive-stage small cell lung cancer (ES-SCLC), and to provide a reference for the clinical treatment of ES SCLC. Methods Twenty-two patients with advanced ES-SCLC admitted to the hospital from September 2015 to February 2018 were selected as the research subjects. 12 first-line patients received apatinib combined with chemotherapy and apatinib single-agent maintenance treatment after chemotherapy. 10 patients and above were treated with apatinib monotherapy, 21 days of treatment was one cycle, and the full analysis set included all patients who had been treated for at least one cycle. Observation and analysis of 22 patients' medication status, efficacy, death, and occurrence of adverse drug reactions. The primary endpoint of treatment is the objective response rate, and the secondary endpoints are progression-free survival (PFS), disease control rate, overall survival (OS) and treatment safety. Results The median OS of 22 patients was 11.1 months, and the median PFS was 5.6 months. Among the 22 patients, 1 case was complete remission, 9 cases were partial remission, 8 cases were stable, and 4 cases progressed: occurred in 22 patients. There were 14 cases (63.6%) of various types of adverse reactions, 5 cases (22.7%) of grade ≥||. The main types of adverse reactions were hand-foot skin reactions, hypertension, and proteinuria. The common adverse reactions of grade ≥ were hypertension and hand-foot skin. reaction. Conclusion Choosing apatinib as the first-line and maintenance treatment of ES-SCLC has good safety, obvious overall curative effect, and has the value of promotion and application. [ABSTRACT FROM AUTHOR]